Tags

Type your tag names separated by a space and hit enter

The role of topical vitamin D modulators in psoriasis therapy.
J Drugs Dermatol 2009; 8(8 Suppl):s4-8JD

Abstract

Psoriasis affects more than 5 million adults in the United States (U.S.), causing significant impairments in quality of life and incurring substantial costs in treatment. The disease is characterized by hyperproliferation and abnormal differentiation of epidermal keratinocytes resulting from a disordered immune response. Topical therapies, such as corticosteroids, are the most common treatment for psoriasis. However, long-term use of more potent topical corticosteroids is associated with potential risk for side effects. Topical vitamin D agents have been developed as a newer therapeutic option for use in place of, or in addition to, topical corticosteroids. These agents act to inhibit keratinocyte proliferation, normalize differentiation and modulate the activity of immune cells with minimal effect on serum calcium hemostasis. Calcipotriene is the most widely used member of this class, and is one of the most frequently prescribed topical agents for psoriasis. Although evidence suggests that it is approximately as effective as low-to-medium potency corticosteroids, it is associated with cutaneous irritation, especially when used in sensitive areas. Calcitriol ointment is a new option for topical therapy and is the only vitamin D3 ointment available for use in the U.S. and contains the naturally occurring active form of vitamin D3 that is associated with a relatively low rate of side effects.

Authors+Show Affiliations

University of California, Davis Medical Center, Sacramento, CA 95819, USA. et@dermatologyandlasersurgery.com

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

19702030

Citation

Tanghetti, Emil A.. "The Role of Topical Vitamin D Modulators in Psoriasis Therapy." Journal of Drugs in Dermatology : JDD, vol. 8, no. 8 Suppl, 2009, pp. s4-8.
Tanghetti EA. The role of topical vitamin D modulators in psoriasis therapy. J Drugs Dermatol. 2009;8(8 Suppl):s4-8.
Tanghetti, E. A. (2009). The role of topical vitamin D modulators in psoriasis therapy. Journal of Drugs in Dermatology : JDD, 8(8 Suppl), pp. s4-8.
Tanghetti EA. The Role of Topical Vitamin D Modulators in Psoriasis Therapy. J Drugs Dermatol. 2009;8(8 Suppl):s4-8. PubMed PMID: 19702030.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The role of topical vitamin D modulators in psoriasis therapy. A1 - Tanghetti,Emil A, PY - 2009/8/26/entrez PY - 2009/8/26/pubmed PY - 2009/9/15/medline SP - s4 EP - 8 JF - Journal of drugs in dermatology : JDD JO - J Drugs Dermatol VL - 8 IS - 8 Suppl N2 - Psoriasis affects more than 5 million adults in the United States (U.S.), causing significant impairments in quality of life and incurring substantial costs in treatment. The disease is characterized by hyperproliferation and abnormal differentiation of epidermal keratinocytes resulting from a disordered immune response. Topical therapies, such as corticosteroids, are the most common treatment for psoriasis. However, long-term use of more potent topical corticosteroids is associated with potential risk for side effects. Topical vitamin D agents have been developed as a newer therapeutic option for use in place of, or in addition to, topical corticosteroids. These agents act to inhibit keratinocyte proliferation, normalize differentiation and modulate the activity of immune cells with minimal effect on serum calcium hemostasis. Calcipotriene is the most widely used member of this class, and is one of the most frequently prescribed topical agents for psoriasis. Although evidence suggests that it is approximately as effective as low-to-medium potency corticosteroids, it is associated with cutaneous irritation, especially when used in sensitive areas. Calcitriol ointment is a new option for topical therapy and is the only vitamin D3 ointment available for use in the U.S. and contains the naturally occurring active form of vitamin D3 that is associated with a relatively low rate of side effects. SN - 1545-9616 UR - https://www.unboundmedicine.com/medline/citation/19702030/The_role_of_topical_vitamin_D_modulators_in_psoriasis_therapy_ L2 - http://www.diseaseinfosearch.org/result/6059 DB - PRIME DP - Unbound Medicine ER -